Amylyx Pharmaceuticals Inc
Save
277.62M
Market cap
Current P/E
2.77x
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases.

Similar securities

Based on sector and market capitalization

Report issue